Invention Summary: Rutgers scientists have discovered a new laboratory process capable of producing novel xenicane (xiolides, xenibelols, florlides, and umbellacins) that are related to diterpenoids in sufficient quantities for drug discovery and development. Bioactive xenicane diterpenoids from natural sources are only isolatable in miniscule quantities that are impractical for a drug development program. Xenicane metabolites are versatile compounds that have been known to exhibit anticancer, antibiotic, antifungal, or anti-HIV activity in the low micromolar range. This new synthetic process enables the production of these natural substances, and more importantly, their unnatural or unknown variants and congeners. The process removes the bottleneck of availability and provides new access to multiple classes of xenicane diterpenoid compounds, analogues, and congeners. The new synthetic route provides significant potential for drug discovery and development due to the dramatically increased number of xenicane diterpenoid compounds available for characterization. Advantages: Synthetic process allows large number of versatile products; Potential products directly promote novel small molecule drug discovery and development; Past publications on the process products have shown numerous potential uses in treatment; Low molecular mass compounds. Market Applications Therapeutics; Drug Discovery; Drug Development; Anticancer; antiviral, anti-HIV; Oncology; Apoptosis; Antibacterial Chemistry; Antibiotics; Antifungals; Drug Adjuvant. Intellectual Property & Development Status: Patent pending.
|Original language||English (US)|
|Publication status||Published - Jan 2020|